A Phase 3, Randomized, Double-Blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension (PALM-PAH)

未提供0 个研究点目标入组 344 人开始时间: 待定

适应症

试验速览

阶段: 不适用
状态: 招募中
入组人数: 344

研究概览研究设计入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional
分配方式: Randomized

入排标准

年龄范围: 18age old over 至 75age old not（—）
性别: All

入选标准

•Participants must have a diagnosis of World Health Organisation (WHO) Group 1 pulmonary hypertension (PAH) in any of the following subtypes, in accordance with European Society of Cardiology European Respiratory Society (ESC/ERS) Guidelines:
•- Idiopathic PAH
•- Heritable PAH
•- Drug/toxin-induced PAH
•- Connective tissue disease (CTD)-associated PAH
•- PAH associated with congenital heart disease-related to simple systemic-to-pulmonary shunt at least 1 year following repair.
•PAH diagnosis for at least 3 months prior to Screening.
•New York Heart Association (NYHA) or World Health Organization (WHO) functional class II-IV.
•Participants must be on stable PAH therapy consisting of 1 to 3 medications from the following classes:
•- Endothelin receptor antagonists (eg, ambrisentan, bosentan, macitentan) for at least 90 days prior to Screening with the last 30 days on stable dose.
•- Phosphodiesterase type 5 inhibitors (eg, sildenafil, tadalafil) for at least 90 days prior to Screening with the last 30 days on stable dose
•- Guanylate cyclase stimulator (eg, riociguat) for at least 90 days prior to Screening with the last 30 days on stable dose
•- Activin signaling inhibitor (e.g., sotatercept) for at least 6 months prior to Screening, with the last 3 months on stable dose and meeting all the following conditions:
•-- no active clinically significant bleeding (eg, epistaxis and gingival bleeding requiring medical interventions) within the past 3 months.
•-- no history of major bleeding events or risks (eg, gastrointestinal or intracranial bleeding) within the past 6 months.
•-- platelet counts greater than or equal to 100,000 per microlitres at Screening
•For both 6-minute walk tests (6MWTs), the values of 6-minute walk distance (6MWD) should be greater than or equal to 150 and lesser than or equal to 450 meters at Screening.
•Right heart catheterization (RHC) at Screening (or within 6 months prior to Screening, if available). Prior RHC may be used provided there has been no change in background PAH therapy and doses. The RHC must meet all of the following hemodynamic criteria:
•- Mean pulmonary arterial pressure (PAP) >20 millimetre of mercury (mmHg) at rest.
•- pulmonary capillary wedge pressure (PCWP) or left ventricular end-diastolic pressure (LVEDP) lesser than or equal to 15 mmHg.
•- pulmonary vascular resistance (PVR) of greater than or equal to 5 wood units (WU).

排除标准

•Diagnosis of PH WHO Groups 2, 3, 4, or 5, or subtypes of PH WHO Group 1 other than described in inclusion criterion 2 (eg, human immunodeficiency virus (HIV), complex congenital heart disease-associated PAH, portal hypertension-associated PAH, pulmonary veno-occlusive disease, Schistosomiasis associated PAH).
•Clinically significant left heart disease, including left-sided valvular disease, left ventricular systolic or diastolic dysfunction, echocardiographic findings suggestive of post-capillary pulmonary hypertension, unstable ischemic heart disease, or unstable arrhythmias.
•Evidence of airflow obstruction defined by forced expiratory volume in 1 second (FEV1) per forced vital capacity (FVC) <0.
•Evidence of significant restrictive lung disease as evidenced by FVC <70% predicted normal.
•Evidence of chronic thromboembolic disease or recent (within 6 months of Screening) acute pulmonary embolism.
•Known hypersensitivity or contraindication to treprostinil or TPIP or TPIP formulation excipients (e.g., mannitol, leucine).
•Any other medical or psychological condition including relevant laboratory abnormalities at Screening that, in the opinion of the Investigator, suggest a new and/or insufficiently understood disease and/or may present an unreasonable risk to the study participant as a result of his/her participation in this clinical trial, may impede their ability complete the study or the study assessments or confound the outcomes of the trial.

研究者

发起方

未提供

相似试验

尚未招募

不适用

A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma (SOLAIRIA-2)Asthma

jRCT203126006796

尚未招募

不适用

A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults (I4V-MC-JAJJ)Diabetes Mellitus, Type 1

jRCT2021250041150

招募中

不适用

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes (J3R-MC-YDAG)Obesity Overweight

jRCT20312508011,980

尚未招募

不适用

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin (J3R-MC-YDAL)Overweight Obesity

jRCT2031250803900

招募中

不适用

A Phase 3 Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features,in Bipolar-I Disorder TakingLithium, Valproate, or Lamotrigine (CN0120046)Bipolar-I Disorder

jRCT204125017027